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Introduction: There are several generic formulations of lamotrigine 
in Serbia that are widely used in the treatment of patients with epi-
lepsy. The reduction of medical costs with use of generic formulations 
has potential risk because of the nature of disease, and it is necessary 
to investigate bioequivalence of each of generic formulations.
Aim: Comparison of the efficacy of the reference and generic for-
mulation of lamotrigine and theinvestigation of lamotrigine serum 
concentrations variation. Date were compared with in vitro results 
of dissolution profiles of the reference and generic tablet formulation.
Patients (or Materials) and Methods: Lamotrigine steady-state con-
centrations were determined by high-performance liquid chromatog-
raphy. In clinical study 16 patients participated, of whom 9 received 
reference formulation and 7 patients received generic formulation. 
Dissolution characteristics were evaluated at 3 points at physiologic 
pH range (pH 1.2, pH 4.5, pH 6.8), and difference (f1) and similarity 
(f2) tests were applied to dissolution data.
Results: The relationship between lamotrigine serum concentration 
(µg/mL) and lamotrigine dose (mg/kg/d) were linear in both formu-
lations (r2 = 0.78484 original and r2 = 0.83417 generic). There are 
statistically significant lower lamotrigine serum concentrations in 
patient treated with original formulation (3.97 [4.1] µg/mL) than 
those in patients treated with generic formulations (5.78 [2.7] µg/
mL). No dose-dependent adverse effects appeared in the patients, 
though patients treated with generic drug were receiving higher doses 
due to assumption that they are less potent. Brand drug had a lower 
standard deviation (SD) and data scattering because, as the dissolu-
tion data showed, it is less influenced by pH changes. Further dissolu-
tion profiles of 2 formulations were only similar in pH 1.2 medium.
Conclusion: Investigation showed equal efficacy of 2 lamotrigine 
formulations, and the variations in plasma concentrations are prob-
ably due to individual characteristics of patients and differences in 
liberation rate of drugs in 2 formulations. It can be claimed that even 
if there are differences in dissolution profiles of 2 drugs they can have 
equal therapeutic efficacy.
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Introduction: Tacrolimus, a potent immunosuppressant, is used for the 
prevention of allograft rejection in organ transplantation. Tacrolimus 
trough concentration (TTC) is still widely used as a guide to individual-
izing tacrolimus dose requirements in renal transplantation. The aim 
was to investigate the effect of patient’s gender on TTC in renal trans-
plant recipients on quaternary immunosuppressive therapy (tacrolimus, 
mycophenolate mofetil, prednisone, and anti–T lymphocyte globulin).
Patients (or Materials) and Methods: Present retrospective case series 
study involved 138 male and 70 female patients subjected to renal 
transplantation. The outpatient examination, recorded in the data-
base of patients from year 2006 to 2008, as the unit of monitoring, 
contained such 3255 male and 1756 female examinations. Tacrolimus 
through concentrations were measured by fluorescence polarisation 
immunoassay (FPIA, TDx, Abbott Laboratories, Chicago, Illinois).
Results: Average TTC in outpatient examinations of male patients 
(7.098 [3.4870] ng/mL) were significantly higher (t = 2.432, P = 
0.015) compared with female transplant recipients (6.852 [3.2726] 
ng/mL).In 25.3% of male examinations, TTC were within the “sub-
therapeutic” range (< 5 ng/mL), while 28.3% of female examinations 
were within the same range; the difference was statistically signifi-
cant. On the other hand, the number of examinations in which the 
TTC were “over the therapeutic” range (> 10 ng/mL) in females were 
significantly lower than in males.
Conclusion: Our results indicated TTC as a useful guide in pointing 
out to potentially relevant influence of sex on its pharmacokinetics, 
what should be routinely considered and further studied.
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Introduction: Pharmacokinetic data of GCV are limited in HSCT 
patients under preemptive therapy and its induced hematologic tox-
icity still problematic.The aim of this study was to evaluate the PK 
of GCV after single and multiple doses in HSCT patients with CMV 
infection and to identify correlation between PK parameters and 
hematologic toxicity.
Patients (or Materials) and Methods: A PK study was conducted 
between October 2008 and December 2009 at MG hospital in Beirut, 
after IV GCV treatment in HSCT recipients with CMV infection. 
CMV disease was recognized by the combination of clinical signs and 
antigenemia. Patients received 1-hour infusion of 5 mg/kg q 12h for 
14 days, and a complete PK study was performed at days 1, 7, and 14. 
A compartmental and no PK analysis were performed, and plasma 
GCV was analyzed by an HPLC validated method with UV detection. 
An ANOVA analysis associated to Freadman test was performed to 
compare the mean PK parameters. The 95% CI was calculated for 
some parameters and P < 0.05 was considered significant.
Results: Twelve patients were enrolled in this study. A significant 
difference in creatinine clearance (Clcr) and trombecytopenia, 
TTC (ng/mL)
Tacrolimus Trough Concentration (TTC); 
No. (%) P value (Chi-square test)
Male Female
< 5 824 (25.3) 497 (28.3) 0.0241
5–10 1931 (59.3) 1028 (58.5) 0.6101
> 10 500 (15.4) 231 (13.2) 0.0386
3255 (100.0) 1756 (100.0)
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occurred between days 1, 7, and 14 (P < 0.0001, P = 0.008, 
respectively). Mean peak concentrations (Cmax) was 9.4 (2.7) μ /
mL (95% CI, 7.3–11.4) and decreased according to the bicom-
partmental model, without any significant accumulation during 14 
days of treatment. Mean minimal concentration were well above 
the CI50 needed to inhibit human CMV. The plasma concen-
trations were not correlated with hematologic effects, indicating 
that the dosage of intracellular GCV is needed to explain this 
induced‐toxicity. The mean half‐life of elimination (t½β ) was 6.4 
(2) hours, and the total clearance of DHPG (CLGCV, 139 [20.4] 
mL/min) was greater and linearly correlated to CLcr (r = 0.930; 
P < 0.0008). The apparent volume of distribution (Vdβ ) was 
(1.2 [0.32] L/kg) higher than that reported to the Solid Organ 
Transplant patients. At steady‐state, an inter‐ and intra‐patient 
variability were observed for CLGCV, t½β , and Vdβ suggesting 
the presence of a subgroup patient.
Conclusion: A population PK should be tested in the future studies 
to identify the best predictor parameter for dosage adjustment to 
improving the most efficacious GCV exposure.
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